Compare Entegris Inc (ENTG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Mesoblast Limited — how do they compare? Entegris Inc trades at $157.96 (market cap $22.95B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Entegris Inc is far larger — about 10.4× Mesoblast Limited's market cap, and Entegris Inc pays a 0.27% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ENTG | MESO | |
|---|---|---|
Market Cap | $22.95B | $2.21B |
Sector | Technology | Technology |
52-Week High | $184.00 | $20.96 |
52-Week Low | $68.80 | $12.88 |
Enterprise Value | $26.16B | $2.21B |
Dividend Yield | 0.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $144.21, down 5.17% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $0.93 EPS, driven by AI-related semiconductor demand. Financials show a net income margin of 9.18% and positive operating cash flow of $695.40M in 2025, though valuation ratios like a P/E of 75.11 appear elevated.
Outlook remains positive due to robust earnings growth and AI tailwinds, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $188.67 price target, suggesting 31% upside, supported by institutional buying interest and strong media sentiment from recent news highlights.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
